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E-mail: brian.bigger@manchester.ac.ukHematopoietic stem cell gene therapy is a promising therapeu-
tic strategy for the treatment of neurological disorders, since
transplanted gene-corrected cells can trafﬁc to the brain, by-
passing the blood-brain barrier, to deliver therapeutic protein
to the CNS. We have developed this approach for the treatment
of Mucopolysaccharidosis type IIIA (MPSIIIA), a devastating
lysosomal storage disease that causes progressive cognitive
decline, leading to death in early adulthood. In a previous
pre-clinical proof-of-concept study, we demonstrated neuro-
logical correction of MPSIIIA utilizing hematopoietic stem
cell gene therapy via a lentiviral vector encoding the SGSH
gene. Prior to moving to clinical trial, we have undertaken
further studies to evaluate the efﬁciency of gene transfer into
human cells and also safety studies of biodistribution and gen-
otoxicity. Here, we have optimized hCD34+ cell transduction
with clinical grade SGSH vector to provide improved pharma-
codynamics and cell viability and validated effective scale-up
and cryopreservation to generate an investigational medicinal
product. Utilizing a humanized NSGmouse model, we demon-
strate effective engraftment and biodistribution, with no vector
shedding or transmission to germline cells. SGSH vector geno-
toxicity assessment demonstrated low transformation poten-
tial, comparable to other lentiviral vectors in the clinic. This
data establishes pre-clinical safety and efﬁcacy of HSCGT for
MPSIIIA.
INTRODUCTION
Mucopolysaccharidosis type IIIA (MPSIIIA), also known as Sanﬁ-
lippo syndrome A, is a severe, progressive, neurodegenerative disor-
der caused by loss-of-function mutations in the N-sulfoglucosamine
sulfohydrolase (SGSH) gene.1 SGSH is one of several essential lyso-
somal enzymes involved in the sequential degradation of the glycos-
aminoglycan (GAG) heparan sulfate (HS).1 Absence of functional
SGSH leads to the abnormal accumulation of partially degraded,
highly sulphated HS in cells throughout the body, resulting in cellularMolecular Therapy: Methods &
This is an open access article under ttoxicity and impaired organ function. The brain is predominantly
affected, and clinical symptoms, which are typically diagnosed at 2
to 4 years of age, include cognitive delay, neurodegeneration, and se-
vere behavioral disturbances.2 In addition, patients also suffer from
non-neurological symptoms, including hepato- and splenomegaly,
digestive tract problems, speech delay, hirsutism, recurrent ear,
nose, and throat infections, and facial dysmorphisms.3 Disease pa-
thology progressively worsens over time, and affected individuals
do not typically survive beyond late teenage years or early adulthood.
Autologous hematopoietic stem cell gene therapy (HSCGT) is an
appealing therapeutic strategy for the treatment of neurodegenerative
lysosomal storage disorders, since patients’ own hematopoietic prog-
eny cells can be genetically engineered to express or overexpress func-
tional lysosomal enzyme. Modiﬁed cells, especially of the macrophage
lineage, can migrate to affected tissues and importantly possess the
ability to pass through the blood-brain barrier (BBB), engraft in the
CNS, and secrete therapeutic enzyme that can be taken up by affected
neurons, thereby enabling the breakdown of the stored material and
cross-correction of afﬂicted cells in the CNS as well as in the periph-
ery.4 Crucially, by increasing the level of functional gene replacement
per genetically modiﬁed cells within hematopoietic stem cells (HSCs)
and their progeny, there is an opportunity for supra-normal enzyme
expression, thereby enhancing efﬁcacy compared to HSC transplant
alone.5,6 The intrinsic self-renewal ability of HSCsmeans that HSCGT
has the potential to be a one-off treatment without the need for
repeated dosing, as is the case with current enzyme-replacementClinical Development Vol. 13 June 2019 ª 2019 The Authors. 399
he CC BY license (http://creativecommons.org/licenses/by/4.0/).
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www.moleculartherapy.orgtherapies. Encouragingly, the HSCGT approach has been successfully
evaluated for the similar metabolic storage disorder metachromatic
leukodystrophy (MLD) and also for the peroxisomal condition
CCALD (childhood cerebral adreno-leukodystrophy) and the pri-
mary immunodeﬁciency disorders adenosine deaminase severe com-
bined immunodeﬁciency (ADA-SCID) and Wiskott-Aldrich syn-
drome (WAS), demonstrating promising clinical outcomes.4,7–11
Alternative MPSIIIA treatment methodologies currently being
evaluated include repeated intracerebrospinal ﬂuid infusions of
recombinant human SGSH (rhSGSH) (https://clinicaltrials.gov/;
NCT #01155778, #01299727, #02060526, #02350816),12–15 direct in-
jection into the brain with AAV vector encoding SGSH and SUMF1
(lysogene SAF 301, NCT #01474343),16–18 and intravenous delivery
of CNS targeting AAV9 vector (scAAV9.U1a.hSGSH) (Abeona
ABO-102, NCT #02716246).19 In addition, a phase I-II clinical trial
using an AAV9 vector containing hSGSH for intracerebroventricular
(ICV) delivery (Esteve-EGT-101) has recently opened and are
currently enrolling patients. Completed MPSIIIA trials to date
have demonstrated limited efﬁcacy in early evaluations, and in
some cases high numbers of severe adverse events have been re-
ported.12 Long-term clinical data from Abeona ABO-102 (NCT
#02716246) is still awaited. AAV gene therapy treatments delivered
directly to the brain are often highly invasive, while systemically
delivered AAV vectors can be costly to scale up, with the potential
to generate undesirable immune responses limiting efﬁcacy of the
treatment.20 Furthermore, a number patients display pre-existing
immunity to AAV serotypes with CNS tropism, limiting the poten-
tial scope of treatment.
We have developed the HSCGT approach for the treatment of
MPSIIIA based on lentiviral-mediated transfer of the SGSH gene un-
der the control of the CD11b promoter to target gene expression to
myeloid cells trafﬁcking to the brain. In a pre-clinical proof-of-
concept study, we previously demonstrated disease correction
following transplantation of gene-corrected autologous SGSH-deﬁ-
cient murine HSCs into busulfan-conditioned MPSIIIA mice.21
Transduction of autologous MPSIIIA HSCs with CD11b.SGSH lenti-
viral vector (LV) normalized the hyperactivity characteristics of the
disease, brain HS, secondary storage, lysosomal compartment size,
and neuroinﬂammation in MPSIIIA mice, whereas a phosphoglyc-
erate kinase mammalian promoter (PGK)-driven vector could only
mediate partial correction in many of these parameters. Increased
SGSH expression frommyeloid-derived cells migrating into the brain
and differentiating into microglia-like cells resulted in improvedFigure 1. GMP LV CD11b.SGSH Is Equivalent to Its Research Grade Counterpa
(A) Vector design. pCCL LV containing a human myeloid CD11b promoter driving expres
transduced with GMP or non-GMP CD11b.SGSH LV at an MOI of 60, then transplante
the donor chimerism inWBCswas determined by flow cytometry (n = 10 per group). (D) V
in methylcellulose culture. (E) Hematopoietic lineage development was assessed by CFU
erythroid (BFU-E); CFU-granulocyte, erythroid, macrophage, megakaryocyte (CFU-GE
blood cells (WBCs), bonemarrow (BM), pooled CFU colonies, and the brain was assesse
colonies and BM 12 weeks post-transplant (one-way ANOVA Kruskal-Wallis test).
Moleculbrain enzyme without changing peripheral enzyme overexpression,
making the CD11b vector more target speciﬁc for the brain.21
Following successful proof of concept in the MPSIIIA mouse model,
here we demonstrate the safety and efﬁcacy of clinical grade GMP
CD11b.SGSH lentiviral vector prior to a ﬁrst in human clinical trial
in accordance with regulatory guidelines, evaluating vector batch
equivalence, optimal dosing, transduction scale-up and cryopreserva-
tion, engraftment, biodistribution, systemic toxicity, and vector
genotoxicity.
RESULTS
GMP CD11b.SGSH LV Is Equivalent to Research Grade LV:
In Vivo Vector-Bridging Study
To develop HSCGT for MPSIIIA patients, we produced a third-
generation self-inactivating (SIN) LV with a codon optimized
SGSH transgene driven by the myeloid-speciﬁc CD11b promoter
(CD11b.SGSH LV), manufactured to good manufacturing practice
(GMP) standard (Figure 1A).21 In order to demonstrate that GMP
vector has the comparable efﬁcacy and safety proﬁle as research-grade
(non-GMP) vector (as used in earlier pre-clinical proof-of-concept
studies21), we devised a short-term in vivo bridging study (Figure 1B).
MPSIIIA recipient mice (CD45.2+ve) were transplanted with either
GMP- or non-GMP LV-transduced MPSIIIA lineage-depleted pro-
genitor donor cells (CD45.1+ve) and evaluated at 12 weeks post-
transplant (Figure 1B). Mean donor cell engraftment for both the
GMP and non-GMP-transduced groups was 87.9% and 88.3%,
respectively (Figure 1C). Flow cytometry analysis of blood high-
lighted some variation in leucocyte composition in individual mice;
however, overall, comparable proportions of donor and recipient
B cells (CD19+), T cells (CD3+), and monocytes (CD11b+) were
observed between the GMP and non-GMP groups (Figure 1C).
Transplants were performed in separate batches as donor and recip-
ient mice became available, with an equal number of GMP and non-
GMP LV-transplanted mice in each batch. There was no difference
in transduction efﬁciency between vector grades in terms of vector
copy numbers (VCNs); however, variation in integrated VCNs was
observed between different transplant batches, likely due to differ-
ences between donor hematopoietic stem-cell-enriched cell lots
(Figure 1D).
At harvest, a proportion of bone marrow was seeded for colony-form-
ing unit (CFU) assay to assess normal lineage development. Similar
numbers of colony types were observed among wild-type (WT),
MPSIIIA, GMP, and non-GMP LV-transplanted groups, suggestingrt In Vivo
sion of codon-optimized SGSH. (B) MPSIIIA bone marrow was lineage depleted and
d into busulfan-myeloablated MPSIIIA mice. (C) Twelve weeks post-transplantation,
CNwas determined for each transplant batch at initial transduction following 14 days
assay 12 weeks post-transplant. CFU-granulocyte, macrophage (CFU-GM); BFU-
MM); CFU-granulocyte (CFU-G); and CFU-macrophage (CFU-M). (F) VCN in white
d 12 weeks post-transplant. (G) SGSH enzyme activity was assessed in pooled CFU
ar Therapy: Methods & Clinical Development Vol. 13 June 2019 401
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(Figure 1E). The VCN was assessed in white blood cells (WBCs),
bone marrow (BM), CFU colonies, and the brain of transplanted
mice, with no differences observed between GMP and non-GMP
groups (Figure 1F). An increase in SGSH enzyme activity was de-
tected in the BM and pooled CFU colonies for both GMP and non-
GMP groups compared to WT and MPSIIIA controls, with no signif-
icant difference between the two. SGSH activity was also measured in
the brain and plasma; however, no increase was observed compared
to non-transplanted MPSIIIA controls after 12 weeks (S.M.E., data
not shown). In the proof-of-concept study performed previously,
11% of wild-type SGSH activity was achieved in the brain of treated
MPSIIIA mice 6 months post-transplant, this suggests 12 weeks
may only allow partial monocyte migration to the brain, insufﬁcient
to achieve signiﬁcant increases in SGSH activity.21 This HSGCT
bridging study conﬁrms clinical GMP-grade SGSH LV is equivalent
to its non-GMP research-grade counterpart in MPSIIIA mice.
CD11b.SGSH LV-Mediated HSCGT Reduces Kidney and
Myocardial Vacuolation in MPSIIIA Mice
A toxicology study was performed on tissues harvested in the vector-
bridging study from GMP and non-GMP LV transplant group ani-
mals and compared to untreated MPSIIIA mice. Key histopathology
ﬁndings were present in kidney, heart, and liver (Table S1). Vacuola-
tion of the tubular epithelium of the distal tubules of the cortex in the
kidney and myocardial vacuolation was seen in both untreated and
treated animals, with the treated animals showing a reduction
in the severity of the ﬁnding over untreated MPSIIIA controls.
Decreased glycogen was observed in the livers of occasional MPSIIIA
mice given cells transduced by non-GMP and GMP LV (3/10 and
4/10, respectively).
Another ﬁnding in the liver included minimal centrilobular hypertro-
phy (3/10) and minimal to slight focal necrosis of the hepatocytes
(3/10). These ﬁndings were only seen in MPSIIIA animals given cells
transduced with GMP LV and were accompanied with an increased
incidence of minimal to slight inﬂammatory cell inﬁltrates in the liver
of these animals (6/10) when compared to all other groups. This
ﬁnding was also present at a low incidence for the non-GMP LV-
treated animals (1/10). It is considered that the focal necrosis and
increased incidence of inﬂammatory inﬁltrates were likely sequelae
of the earlier myeloablative conditioning, with the incidence in the
affected animals being completely random and not due to the vector
grade. Myeloablative conditioning was achieved with the use of
busulfan, the formulation of which is known to be hepatotoxic,
causing lesions similar to those observed here.
CD11b LV Effectively Transduces Human Hematopoietic Stem
Cells
In order to investigate transduction efﬁciency of human hematopoi-
etic stem cells with the CD11b-driven LV, we ﬁrst utilized a LV ex-
pressing GFP (CD11b.GFP LV) to allow simple visualization of trans-
duced cell progeny. Umbilical-cord-blood-sourced CD34+ cells were
transduced at an increasing MOI range of 10, 30, and 100, with an402 Molecular Therapy: Methods & Clinical Development Vol. 13 June 2MOI of 100 used in several completed clinical studies.4,22 Transduced
CD34+ cells were plated in methylcellulose culture for 14 days, and
the percentage of GFP +ve cells for each LV dose was determined.
As expected, an MOI of 100 provided the highest transduction efﬁ-
ciency of 63%, signiﬁcantly higher than MOIs of 10 and 30 (Fig-
ure 2A).We further evaluated the pattern of transduction for different
hematopoietic progenitor types and observed similar numbers of
transduced progenitors (Figure 2B).
An effective HSCGT requires sufﬁcient HSC genetic manipulation to
provide a therapeutic level of disease correction without impairing
normal stem cell expansion or causing adverse effects. We therefore
evaluated the optimal transduction dose of our therapeutic
CD11b.SGSH LV in human CD34+ cells. Experiments were designed
to both evaluate single versus double transduction and to conﬁrm
equivalence between GMP- and non-GMP-grade LV batches
in vitro. Mock-transduced cells undergoing the same manipulations
as transduced cells but without culture in the presence of lentiviral
vector were included as controls. Overall transduction efﬁciency
was high following both single transduction (TDX1) and double
transduction (TDX2) with both vector grades and with similar pro-
portions of erythroid burst-forming unit (BFU-E) and colony-form-
ing unit (CFU) colonies transduced (Figure 3A). TDX1 resulted in
VCNs in pooled CFU colonies of 2.58 and 2.1 for GMP and non-
GMP, respectively, compared to 3.89 (GMP) and 4.63 (non-GMP)
for TDX2 (Figure 3B). There was no change in VCN between vector
grades; however, a statistically signiﬁcant difference was observed be-
tween single and double-transduced CD34+ cells. SGSH enzyme ac-
tivity also improved considerably following a double transduction
with either vector grade giving a 68.4 (GMP) and 58.6 (non-GMP)
fold increase in SGSH enzyme activity over mock-transduced cells
compared to a 31.6 (GMP) and 36.6 (non-GMP) fold increase
following a single transduction (Figure 3C). Furthermore, there was
no signiﬁcant difference in SGSH activity between GMP and non-
GMP transduced groups, conﬁrming vector comparability. The dis-
tribution of hematopoietic progenitors for all groups also followed
a normal pattern indicating no lineage skewing (Figures 3D and
3E). The yield of cells recovered after 14 days in CFU culture from
those cells incubated for 48 hours (TDX2 mock-transduced) was
equivalent to cells incubated for 24 hours (TDX1 mock-transduced
cells) (Figure 3F). Transduction experiments were repeated four times
in total, with CD34+ cells sourced from either umbilical cord blood
(UCB) or mobilized peripheral blood (MPB) (Figure 3G and data
not shown). Achievable VCNs from a single transduction of
hCD34+ cells ranged from 1.73 to 7.81 with a median of 2.34
compared to a double transduction, where the VCN ranged from
3.89 to 11.06 with a median of 4.95 (Figure 3G).
Effective Scale-Up of hCD34+ Cell Transduction and
Cryopreservation
In the clinical setting, a dose in the region of > 5  106 transduced
CD34+ cells/kg will be needed in order to treat patients.4 Further-
more, transduced cells will require cryopreservation in order to pro-
vide sufﬁcient time for shipment of drug product to the local hospital019
Figure 2. Characterization of Human CD34+ Cell Transduction with CD11b.GFP LV
(A) Umbilical cord blood (UCB) hCD34+ cells were transduced with an increasing MOI of CD11b.GFP LV and transduction efficiency determined by counting GFP-positive
colonies following colony-forming unit (CFU) assay (*p < 0.05, **p < 0.01). (B) hCD34+ cells were transduced with CD11b.GFP LV at an MOI of 100 and the transduction
efficiency evaluated in BFU-E, CFU-GEMM, CFU-GM, CFU-M, and CFU-G progenitors. Representative images of CD11b.GFP LV transduced progenitors.
www.moleculartherapy.organd conditioning of the patient after drug product release prior to
transplant. We performed a large-scale CD34+ cell transduction vali-
dation run, using GMP grade LV under GMP-like conditions
including a cryopreservation step ofR 6 weeks (52 days) to replicate
manufacture of an investigational medicinal product (IMP) and sup-
porting stability of cryopreserved formulation of drug product. HSCs
were isolated from a MPB apheresis unit by immuno-magnetic
CD34+ cell selection. An initial pre-stimulation step was performed
with 60 106 CD34+ cells followed by two rounds of LV transduction
at an MOI of 100 in accordance with the likely future clinical trans-
duction protocol to achieve maximal levels of CD34+ cell transduc-
tion and integrated vector copies. Mock-transduced CD34+ cells
were included as controls.
The percentage of viable CD34+CD45+ cells post-selection, pre-trans-
duction, post-TDX1, post-TDX2, and post-mock-transduction (both
single and double) were all 96% or above (Figure 4A). Furthermore,
cryopreservation of cells post-TDX1 or -TDX2 had no adverse effect
on cell viability, with 99.5% and 98.8% viable CD34+CD45+ cells re-
corded, respectively. Post-thaw cell counts and viability (trypan blue
staining) for TDX1 and TDX2 samples are summarized in Figure 4B.
Viable cell recovery post-thaw was 91.1% for TDX1 and 82.4% for
TDX2. A double transduction at large scale achieved a higher VCN
than a single transduction, 5.6 (TDX2) versus 4.02 (TDX1), respectively
(Figure 4C), comparable to VCNs achieved at small scale (Figure 3F).
Post-cryopreservation, similar VCNs of 5.33 (TDX2) and 3.2 (TDX1)
were recorded. A similar pattern of CFU and BFU-E progenitors was
observed for both TDX1 and TDX2 post-cryopreservation in the
CFU assay (Figure 4D); however, we observed a drop in total numberMoleculof colonies recovered in the TDX2 group compared to TDX1 (62.8
versus 94.5 total colonies, respectively). SGSHenzymeactivity remained
the same in transduced cells (TDX2 group) before and after cryopreser-
vation (Figure 4E). The large-scale validation run demonstrates that
transduction of CD34+ cells with GMP CD11b.SGSH LV can be effec-
tively scaled up for the clinic and that 52 days cryopreservation has no
detrimental effect on efﬁcacy or cell viability.
Normal Engraftment and Biodistribution of SGSH LV-
Transduced CD34+ Cells in a Humanized Mouse Model
An engraftment and biodistribution study was performed to evaluate
if transduction of human CD34+ cells with GMP SGSH LV affects
their ability to engraft, differentiate, and distribute to hematopoietic
organs in a humanized mouse model. Although HSCs sourced from
umbilical cord blood demonstrate greater engraftment potential in
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice23 (Figure S1),
HSCs isolated from mobilized peripheral blood were chosen as the
preferred source, since they more closely represent the autologous
cells to be used in the clinic. Here, we utilized the 52 day cryopre-
served, TDX2 and mock-transduced (MOCK) CD34+ cells from the
large-scale transduction validation run. An overview of the study
design is depicted in Figure 5A. Mice were treated with a partial mye-
loablative dose of 25 mg/kg busulfan (Bu) 24 h prior to transplant.
Engraftment of human leukocytes and differentiation into speciﬁc
lineages was evaluated in the hematopoietic organs (BM, spleen,
and thymus) and peripheral blood (PB) of NSG mice 16 weeks
post-transplant (Figure 5B). The thymus demonstrated the highest
level of human cell engraftment, with average hCD45+ cellar Therapy: Methods & Clinical Development Vol. 13 June 2019 403
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Figure 4. CD34+ Cell Transductions Scaled Up and Cryopreservation Validated for Clinical Application
(A) CD34+ cell purity and viability accessed by flow cytometry at post-selection, post-prestimulation, post-transduction, and post-cryopreservation. (B) Post-thaw cell counts,
viability, and total cell percentage recovery at 52 days after cryopreservation. (C) VCN of bulk liquid culture transduced cells pre- and post-cryopreservation for TDX1 and
TDX2 cell groups. (D) The CFU assay was performed post-cryopreservation and the number of BFU-E and CFU colonies determined for TDX1 and TDX2 groups.
(E) Evaluation of SGSH activity in transduced cells pre- and post-cryopreservation.
www.moleculartherapy.orgengraftment levels of 89.9% and 89.5% for the mock and TDX2
groups, respectively (Figure 5B). In the BM, engraftment was
9.0% and 3.8%, in the spleen 12.2% and 8.9%, and in the WBCs
4.5% and 1.5% for the mock and TDX2 groups, respectively. There
was no signiﬁcant difference in hCD45+ cell engraftment between
mock and TDX2 groups in the individual organs tested (two-way
ANOVA multiple-comparison post-hoc Tukey test). We further
investigated the leucocyte compositions in the hematopoietic or-
gans. In the thymus, the primary lymphoid organ of the immune
system where T cells mature, there were equivalent proportions of
CD3+, CD4+, CD8+, and CD4+CD8+ cells between the mock and
TDX2 treatment groups (two-way ANOVA multiple comparison
test) (Figure 5C). In the BM, we observed equivalent stem cell
(CD34+), myeloid (CD13+), and B cell (CD19+) populations be-
tween the mock and TDX2 groups (Figure 5D). In the spleen, we
evaluated T, B, myeloid, and stem cells populations. Equivalent pop-
ulations were observed for all cell types between mock and TDX2
groups apart from the T cell population, where there was a slight
elevation in CD3+ and CD4+ cells (CD3+, p < 0.0001; CD4+, p =
0.03) in the TDX2 group (Figure 5E). Human cell engraftment inFigure 3. CD11b.SGSH LV Equivalence Testing and Dose Optimization in CD34
hCD34+ cells were transduced with GMP or non-GMP LV at an MOI of 100 and eva
compared. (A) Transduction efficiency determined by qPCR assessment of individual
transgene (n = 16 BFU-E; n = 16 CFU colonies). (B) VCN determined in pooled CFU colon
0.0001). (D) CFU progenitor counts following TDX1 or TDX2. (E) CFU progenitor counts
times with different batches of CD34+ cells and the VCN range for TDX1s and TDX2s e
MoleculWBCs was low, making speciﬁc leucocyte populations difﬁcult to
evaluate accurately.
Effective Biodistribution and Efficacy of the IMP in NSG Mice
with No Vector Shedding or Toxicity
Evaluating IMP biodistribution in the body provides important
insight into which organs are potential therapeutic targets and can
also identify possible off target effects such as gene transfer to the
reproductive organs. We evaluated distribution of transduced hu-
man cells in non-hematopoietic organs, including the liver, heart,
lungs, kidney, brain, and gonads in addition to the spleen, thymus,
WBCs, and BM. Biodistribution was measured in the TDX2 group
(n = 18) by qPCR using a method that only detects integrated vector
in human cells (primer-probe sets speciﬁc for integrated vector and
human housekeeping gene). Importantly and consistent with the in-
tended mode of action to treat MPSIIIA, transduced human cells
were detected in the brain (12 out of 18). Transduced human cells
were also identiﬁed in the BM (15/18), WBC (6/18), thymus
(8/18), spleen (16/18), heart (7/18), liver (17/18), kidney (18/18),
and lung (18/18) but undetectable in the gastrocnemius muscle+ Cells
luated in the CFU assay. Single (TDX1) versus double (TDX2) transductions were
colonies and calculating the percentage of positive colonies containing integrated
ies by qPCR (**p < 0.005). (C) SGSH enzyme activity in pooled CFU colonies (****p <
following TDX2. (F) Total CFU colony counts. (G) The experiment was repeated four
valuated.
ar Therapy: Methods & Clinical Development Vol. 13 June 2019 405
Figure 5. NSG Engraftment and Biodistribution Study
(A) NSG engraftment and biodistribution study design. (B) Human leucocyte (CD45+ cells) engraftment in the hematopoietic organs of NSG mice transplanted with TDX2 or
mock-transduced, 52 day cryopreserved human CD34+ cells from PBMCs. (C) Human T cell populations in the thymus of transplanted mice. (D) Stem cell (CD34+), myeloid
cell (CD13+), and B cell (CD19+) populations in the BM of transplanted mice. (E) T cell (CD3+, CD4+, CD8+), stem cell (CD34+), myeloid cell (CD13+), and B cell (CD19+)
populations in the spleens of transplantedmice (*p <0.05, ****p < 0.001). (F) VCN per human cell was determined in the BM,WBCs, thymus, spleen, brain, heart, liver, kidney,
lungs, gastrocnemius muscle, and gonads of TDX2 transplanted mice by qPCR. VCNwas also determined for transduced cells before transplant (bulk LC [liquid culture]) (G).
SGSH enzyme activity in the BM of mock- and TDX2 transplanted NSG mice (****p < 0.0001).
Molecular Therapy: Methods & Clinical Development(0/18) and also the gonads (0/18), suggesting no potential for germ-
line transmission. The average VCN per human cell in the BM was
6.6, WBC 7.0, thymus 4.9, spleen 4.3, brain 6.7, heart 5.1, liver 3.6,406 Molecular Therapy: Methods & Clinical Development Vol. 13 June 2kidney 4.6, and lung 4.1 of TDX2 animals (Figure 5F). The average
VCN of all organs tested (both hematopoietic and non-hematopoi-
etic) was equivalent to the VCN of transduced human cells (bulk019
(legend on next page)
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(Figure 4C). Efﬁcacy of treatment was conﬁrmed by the signiﬁcant
increase in BM SGSH enzyme activity in the TDX2 group compared
to the mock group (Figure 5G). This reﬂects the 4% of human cells in
the background of normal mouse BM that naturally have low SGSH
activity levels.
Since this is an ex vivo stem cell gene therapy technique, we did not
expect to observe vector shedding from transplanted transduced cells.
Indeed, p24 ELISA conﬁrmed undetectable levels of capsid protein in
the plasma and urine of treated mice (Table S2). For toxicology anal-
ysis, blood and BM smears and formalin ﬁxed samples of brain, heart,
kidneys, liver, lungs and bronchi, skeletal muscle, spleen, and testes or
ovaries were sent for H&E staining and evaluation by Envigo. Hema-
tology and histopathology ﬁndings reported no differences between
mock- and TDX2-treated NSG mice (Figures S3 and S4).
LV CD11b.SGSH Demonstrates Low Transformation Potential
A long-term concern regarding the clinical use of lentiviral vectors is
the risk of insertional mutagenesis. The in vitro immortalization
(IVIM) assay has proved to be an effective tool to evaluate genotox-
icity by determining transformation events in virally transduced
murine lineage negative stem and progenitor cells under myeloid
differentiation conditions.8,24 We evaluated CD11b.SGSH vector
against a positive control gamma-retroviral vector, gRVSF91GFP,
which has an intact LTR comprising of the promoter and enhancer
element of spleen focus-forming virus known to cause transforma-
tion events. A further control of a SIN LV with an internal SFFV
promoter driving GFP (LV EFS GFP [lentimax]) was also included.
The gRVSF91GFP-positive control vector generated high levels of
transformation and cell proliferation, with markedly lower levels
observed for the CD11b.SGSH vector with only a slight elevation
in transformation events compared to lentimax negative control,
although this was not signiﬁcantly different (Figure 6A). The replat-
ing index (replating efﬁciency/VCN), which provides a relative mea-
sure of transformation potential, was determined separately at two
institutions and conﬁrmed the low transformation ability of the
CD11b.SGSH vector (Figure 6B, i and ii).
Cryptic splice sites can cause pre-genome splicing during vector
production, leading to generation of defective transgenes. In addi-Figure 6. CD11b.SGSH LV Genotoxicity
(A and B) In vitro immortalization (IVIM) assay. Murine Lin cells transduced by the indic
qPCR for VCN measurement. On day 15, cells were plated into 96-well plates at a dens
showing abundant cell growth were counted as positive, and the frequency of replating
Technologies, Vancouver, Canada). (A) WST-1 colorimetric proliferation assay to determ
for VCN group by investigators at GOSH, UK (i) and University of Manchester (ii). Horiz
CD34+ cells were transduced with LV-CD11b.SGSH at an MOI of 10. Seventy-two ho
amplify the integrated transgene with primers upstream of CD11b and downstream of W
transduced 293T cells (lane 2) and SGSH genome plasmid control (lane 3) were run on
transcript in LV-CD11b.SGSH transduced cells. No other prominent bands were dete
LV-CD11b.SGSH-transduced CD34+ cells (ii) (lane 4, non-template control; lane 5, SG
transduced).
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have immunogenic or toxic potential. To evaluate the presence of
cryptic splice sites, human embryonic kidney 293T cells and
human CD34+ cells were transduced with CD11b.SGSH LV and
incubated for 72 h. Genomic DNA was extracted and PCR per-
formed to evaluate the presence of full-length integrated transcripts.
PCR primers were designed to bind upstream of the CD11b pro-
moter and downstream of the woodchuck hepatitis virus (WHP)
posttranscriptional regulatory element (WPRE) promoter to amplify
a 4.1-kb region of integrated genome sequence. No prominent
smaller bands were detected after gel electrophoresis of the PCR
product, suggesting absence of any truncated transcripts (Figure 6C).
This conﬁrms incidence of splice-truncated vector is negligible with
CD11b.SGSH LV.
DISCUSSION
Pre-clinical safety and efﬁcacy studies are of paramount importance for
the translation of new gene therapies to the clinic.We have developed a
potentially promising approach of lentiviral-vector-mediatedHSC gene
therapy for the treatment of MPSIIIA, where the neurological pheno-
type of the condition is targeted by cross-correction. In this work, we
performed the necessary studies typically required by the regulatory
agencies before a ﬁrst-in-human clinical study can be initiated in
MPSIIIApatients.We conﬁrmedequivalence amongLVbatches, deter-
mined an optimal transduction strategy of human HSCs, effectively
scaled up the transduction process, and evaluated the effect of cryopres-
ervation on transduced cells. Furthermore, we demonstrated effective
engraftment and appropriate biodistributionof the IMP in a humanized
mouse model and conﬁrmed low vector genotoxicity.
The level of SGSH expression is likely to strongly inﬂuence the degree
of MPSIIIA disease correction, given that standard allogeneic stem
cell transplant with wild-type SGSH expression is ineffective in cor-
recting the clinical phenotype in both MPSIIIA animal models and
patients.25–27 We therefore evaluated the appropriate SGSH LV
MOI required to achieve efﬁcacy in human CD34+ cells without
adverse toxicity. We predict an effective target number of integrated
vector copies to be between 2 and 5 per cell, based on other current
HSCGT studies and clinical trials.4,22 Following a single transduction
(at MOI 100), the median VCN achievable from four independent
CD34+ cell transduction experiments was 2.34, compared to 4.95ated vectors were expanded as mass cultures for 2 weeks. An aliquot was taken for
ity of 100 cells/well or 1,000 cells/well in 100 mL medium. Two weeks later, the wells
cells was calculated based on Poisson statistics using L-Calc Software (StemCell
ine positive growth above baseline (red line) (n = 2). (B) Replating frequency corrected
ontal bars indicate mean values. (C) Cryptic splice site assessment. (i) 293T and (ii)
urs after transduction genomic DNA was isolated from cells and PCR performed to
PRE. (i) PCR products from LV-CD11b.SGSH transduced 293T cells (lane 1), non-
an electrophoresis gel. A strong band was observed at 4.1 kb indicating full-length
cted, suggesting an absence of splice mutants. The same finding was observed in
SH plasmid control; lane 6, non-transduced control; and lane 7, LV-CD11b.SGSH
019
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range. There is argument to use a higher VCN to boost SGSH activity
levels, further enhancing the likelihood of therapeutic beneﬁt in pa-
tients, particularly as we expect a minimal threshold level of activity
of approximately 8.5% normal levels required to correct brain neuro-
pathology as previously determined.6,21 MPSIIIA patients have a poor
prognosis, with no effective treatments currently available and the po-
tential beneﬁt of SGSH overexpression is important. Although there is
no evidence that increased vector copies lead to a higher risk of inser-
tional activation, it is likely that in future studies, regulatory agencies
may ask for an upper limit on VCN, hence our plan to target a limit of
ﬁve vector copies. Ideally, we would have evaluated transduction of
MPSIIIA patient CD34+ cells; however, to date we have been unable
to source any MPSIIIA patient HSCs. Encouragingly, murine
MPSIIIA HSCs transduced equally as well asWT, so we do not expect
MPSIIIA HSC transduction to prove problematic.21
The equivalence study ﬁndings demonstrate that SGSH LV manufac-
tured at GMP clinical grade maintains the ability to transduce and
overexpress SGSH enzyme in both lineage-depleted MPSIIIA murine
HSCs and human HSCs. Given these results, a simple comparison
study in CD34+ cells will likely be sufﬁcient to demonstrate consis-
tency between vector batches prior to clinical use. In our studies,
we observed variability in LV transduction efﬁciency between
different batches of HSCs, an important consideration when devising
the treatment strategy for patients. Notably the fold activity of SGSH
per VCN was higher in human CD34+ cells than in murine lin cells.
This reﬂects a 2- to 3-fold lower baselineWT/normal level of SGSH in
human cells and a higher percentage of cells transduced—typically
80%–85% in hCD34+ cells versus 70%–80% in murine lin cells.
We effectively performed a large-scale transduction validation run,
mimicking the CD34+ cell numbers, and expected LV dosing require-
ments similar to those that will be utilized in the clinical setting. Since
patients will require time to receive full myeloablative treatment prior
to transplant, we also evaluated the feasibility of cryopreserving trans-
duced cells. We demonstrated that cryopreservation of transduced
CD34+ cells forR 52 days has a negligible inﬂuence on pharmacody-
namic effects, as measured by enzyme activity, and CD34+ cell viability.
Both VCN and SGSH activity were comparable in transduced cells
before and after cryopreservation. We did observe up to 20% cell loss
after thawing, which will need to be accounted for when calculating
cell doses for transplant. The CFU assay performed post-cryopreserva-
tion of the large-scale double-transduced product showed a reduction
in cell recovery of approximately 33% compared to the single-trans-
duced product, a ﬁnding not observed at small scale in non-cryopre-
served cells but that will, however, need to be considered when ﬁnal-
izing patient gene modiﬁed cell-dosing strategy for the clinic.
We utilized the humanized NSG mouse model to evaluate the effec-
tiveness of SGSH LV-transduced HSC engraftment, identify which
organs they distribute to, and evaluate any toxicological effects or po-
tential for vector shedding.We adopted a dosing protocol that mimics
the proposed clinical protocol, using intravenous administration withMoleculthe appropriate safety margins, i.e., assessing the highest expected
treatment dose (MOI 100 and double-transduced cells). Mice were
not extended out beyond 16 weeks due in part to the high prevalence
of spontaneous thymic lymphomas in older NSG mice and increased
incidences of premature death, which would make interpretation of
treatment-related histopathological ﬁndings difﬁcult.28 NSG mice
can only tolerate a partial myeloablative dose of busulfan; as such,
HSC engraftment is not as high as observed in MPSIIIA mice that
can tolerate a full conditioning regime. Furthermore, HSCs sourced
from PBMC do not engraft as effectively as UCB sourced HSCs in
NSG mice; however, the cell source of choice for patients will be their
own PBMCs. Nonetheless, we were able to demonstrate successful
engraftment of double-transduced and cryopreserved PBMC-derived
CD34+ cells in the hematopoietic organs of transplanted NSGmice at
comparable levels to mock-transduced cells. Furthermore, the pattern
of engraftment we observed was comparable to similar studies con-
ducted by Visigalli et al.29 to evaluate engraftment of iduronidase
(IDUA) LV-transduced healthy donor HSPCs for MPSI and by Car-
bonaro et al.8 evaluating pre-clinical safety of HSCGT for ADA-
SCID, both of which utilized UCB-CD34+ cells as their donor source
without any cryopreservation. Our ﬁndings demonstrate that cryo-
preservation of the IMP is a viable strategy for future autologous he-
matopoietic stem cell gene therapies.
Finally, to assess the insertional mutagenesis potential of the SGSH
LV, we used the in vitro platform established by Modlich et al.24
Low incidence of transformation events in the CD11b driven SGSH
LV demonstrates the relative safety of these SIN design vectors with
their internal mammalian promoters and was comparable to other
SIN vectors currently used in the clinic.8,30 Integration site analysis
in human cells will be evaluated as one of the safety parameters during
phase I-II clinical trial.
Taken together, these studies demonstrate that genetic modiﬁcation
of CD34+ cells using CD11b.SGSH LV fulﬁlls the essential pre-clinical
safety and efﬁcacy requirements prior to commencing a phase I-II
HSCGT clinical trial in MPSIIIA patients.
MATERIALS AND METHODS
Manufacture and Titer of Lentiviral Vector
Research grade pCCLsin.hCD11b.SGSH.DWPRE (CD11b.SGSH LV)
was produced and titer determined as previously described.6,21 Clin-
ical grade CD11b.SGSH LV was produced under GMP at King’s Col-
lege London Vector production facility and quality control (QC)
testing prior to vector release was performed by Bioreliance (UK).
The infectious titer for GMP vector was determined on a human
HT29 cell line with serial dilutions of vector, calculating the inte-
grated vector by validated qPCR assay at University College London
as previously described.8
Experimental Animals
All in vivo procedures were ethically approved under UK Home Of-
ﬁce regulations. Mice were housed in a 12-/12-h light/dark cycle with
food and water provided ad libitum.ar Therapy: Methods & Clinical Development Vol. 13 June 2019 409
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MPSIIIA mice31 on a C57BL/6J background (B6.Cg-Sgshmps3a/6J)
were maintained by heterozygote breeding.6,21,32,33 MPSIIIA back-
crossed to PEP3 CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ) were used to
distinguish donor and recipient cells as previously described.6 WT
littermate controls were used throughout.
NSG Mice
NSG mice were obtained from The Jackson Laboratory (USA) and
bred in-house.34
C57BL/6 Mice
For IVIM assays at University of Manchester and University College
London, 7-week-old C57BL/6 inbred mice were purchased from
Harlan Labs (UK).
Isolation, Transduction, and Transplantation of Murine MPSIIIA
BM lin– HSCs
Donor BM cells were harvested by ﬂushing tibias, femurs, and the
pelvis of age-matched MPSIIIA/PEP3 (CD45.1+ve) mice. Isolated
cells were then lineage depleted and hematopoietic stem cells trans-
duced with GMP or non-GMP LV at an MOI of 60 as described
previously.6 Recipient mice at 2 months of age were treated with
intraperitoneal 125 mg/kg busulfan (Busilvex; Pierre Fabre) over
5 days prior to tail-vein injection of 3  105 LV-transduced he-
matopoietic stem cells. Hematopoietic stem cell engraftment was
assessed in PB following staining with anti-mouse CD45.1-PE
(donor) and CD45.2-FITC (recipient), CD3, CD11b, and CD19 an-
tibodies (BD PharMingen) and analyzed on a BD FACS Canto II
ﬂow cytometer.
CD34+ve Cell Isolation, Transductions, and CFU Assay
CD34+ cells were isolated from mobilized PB, BM (NHS REC), or
umbilical cord blood (soured from ethically approved Anthony No-
lan trust) by magnetic separation following the manufacturers pro-
tocol (Miltenyi Biotec, UK). In brief, human cord blood or human
BM was diluted 1:1 with Hanks balanced salt solution and layered
over Ficoll Histopaque 1077 (Sigma) in 50 mL centrifuge tubes
and centrifuged (no brake) at 480  g for 30 min at room temper-
ature. The mononuclear cells (the buffy coat) were harvested and
CD34+ cells were isolated by immunomagnetic separation with
the Miltenyi MACS CD34+ cell isolation kit (Miltenyi Biotech,
UK). Cells were counted and either transduced as freshly isolated
CD34+ cells or cryopreserved (freezing medium, 90% serum and
10% DMSO) and then transduced after thawing. CD34+ cells were
seeded in growth medium (x-vivo 15 + 1% human serum albumin,
20 ng/mL recombinant human-interleukin-3 [rh-IL-3], 300 ng/mL
rh-stem cell factor [rh-SCF], 300 ng/mL rh-fms-like tyrosine kinase
3 ligand [rh-FLT3L], and 100 ng/mL rh-thrombopoietin [rh-TPO];
Peprotech, UK) at a density of 0.5–1  10E6 cells/mL and pre-stim-
ulated overnight for 18 ± 2 hrs. Cells were then transduced once
(TDX1) with either GMP or non-GMP CD11b.SGSH LV at an
MOI 100 for 16–18 hrs with cytokines. A proportion of these cells
were seeded for CFU assay following manufacturer’s protocol (Stem410 Molecular Therapy: Methods & Clinical Development Vol. 13 June 2Cell Technologies), while the remainder underwent a second round
of transduction (TDX2) with either non-GMP or GMP
CD11b.SGSH LV at an MOI 100 for a further 24 hrs prior to seed-
ing in CFU assay.
Large-Scale Transduction and Cryopreservation
CD34+ cells were positively selected from two pooled PB mononu-
clear cell (PBMC) apheresis units (Allcells, USA) using the Miltenyi
CliniMACSPlus instrument and reagents according to the manufac-
turer’s instructions. The selection yielded a total of 2.5  108 viable
cells, with a purity of 99.5% CD34+ conﬁrmed by ﬂuorescence-acti-
vated cell sorting (FACS). For pre-stimulation, cells were placed in
growth media (X-VIVO 15 supplemented with 1% human serum
albumin (HSA), IL-3 (20 ng/mL), SCF (300 ng/mL), FLT3-L
(300 ng/mL), and TPO (100 ng/mL) (Peprotech) and seeded in a
118-C VueLife ﬂuorinated ethylene propylene (FEP) culture bag
at a density of 1  106/mL. After approximately 22 hrs of pre-stim-
ulation, cells were harvested, and a QC sample was taken for count-
ing, viability, ﬂow cytometry (CD34/CD45), and baseline control for
VCN assay (VCN in bulk) and CFU assay (CFU counts). At that
point cells were split into two arms: a transduction arm and a
mock arm. Remaining cells were cryopreserved for downstream
QC testing.
Transduction Arm
GMP SGSH-LV was added at an MOI of 100 (1  108 TU/mL) to
60  106 cells in growth media. The cells and vector mix (a total of
60 mL, cells at 1  106/mL) was divided evenly between 2 32-C
bags and placed in the incubator for the ﬁrst round of transduction
(21 hrs). Following transduction, cells were harvested, pooled, and
washed by centrifugation. After counts and viability, QC samples
were distributed for ﬂow cytometry (CD34/CD45), VCN assay
(bulk only), and CFU assay (counts). A total of 60  106 cells were
set aside in growth media, and GMP SGSH-LV was added for a sec-
ond round of transduction. After the second and ﬁnal round of trans-
duction, cells were harvested, washed by centrifugation, and re-sus-
pended in X-VIVO 15/1% HSA. QC samples were taken for counts,
viability, CD34/CD45 phenotype, VCN assay (bulk and picked
CFU), CFU assay (counts), and SGSH activity (pooled CFUs).
Mock-Transduction Arm
45  106 cells were set aside in growth media at a density of 1 
106/mL and transferred into a 45-C VueLife FEP culture bag for
mock transduction 1. After 22.5 hr, cells were harvested, washed
by centrifugation. After counts and viability, QC samples were
distributed for ﬂow cytometry (CD34/CD45), VCN assay (bulk
only), and CFU assay (counts). 45  106 cells were set aside in
growth media at a density of 1  106/mL and transferred into a
45-C VueLife FEP culture bag for mock transduction 2. Leftover
cells were cryopreserved as described in section 4.3. After approxi-
mately 20 hrs, cells were harvested and washed by centrifugation.
QC samples were taken for counts, viability, CD34/CD45 pheno-
type, VCN assay (bulk and picked CFU), CFU assay (counts), and
SGSH activity (pooled CFUs).019
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Cells were cryopreserved in CryoStor 10 at 5  106 cells/mL per vial
using a control rate freezer (Planer Kryo 560).
Transplantation of Human HSCs in NSG Mice
An equal number of male and female NSGmice (7–9 weeks old) were
pre-conditioned with 25 mg/kg busulfan delivered by intraperitoneal
(i.p.) injection 24 hr prior to transplant. Cryopreserved cells were
thawed at 37C and gently washed twice in RPMI media. Cells
were administered intravenously by tail-vein injection at 4 105 cells
per mouse. The health of the mice was monitored daily and weights
measured weekly throughout the study (Figure S3). Sixteen weeks
post-transplant, mice were euthanized by i.p. injection with a lethal
dose of pentobarbital (0.8 mL/kg). PB samples were collected by car-
diac puncture, animals were perfused with PBS to eliminate any
contaminating blood, and speciﬁed organs were harvested for down-
stream processing. Seven out of the ﬁfty experimental mice were
culled before the end of the study due to signs of sickness and ill
health, not uncommon with immunocompromised NSG mice.
A further three animals were excluded from the study due to low
engraftment (<1% human cells in two or more organs). Of the re-
maining 40 animals, 22 were from the mock treatment group (10 f,
12 m) and 18 from the TDX2 treatment group (11 f, 7 m).
VCN Analysis
For the murine MPSIIIA equivalence studies, the number of integra-
tions was determined by qPCR using the WPRE and rodent GAPDH
primer probe sets described,21 and a standard curve generated
by serial dilution of DNA sample derived from an EL4 cell line
clone (ALS EL4 eGFP 2.2) containing two copies of integrated
WPRE gene/cell. For determination of VCN in human cells, qPCR
was performed using the vector-speciﬁc WPRE primer-probe set21
and a human syndecan 4 gene (SDC4) speciﬁc primer-probe set
(forward primer 50-cagggtctgggagccaagt-30, reverse primer 50-gca
cagtgctggacattgaca-30, probe 50-VIC-cccaccgaacccaagaaactagagga
gaat-TAMRA-30). A standard curve was generated by serial dilution
of genomic DNA (gDNA) sample derived from a human HTC116
cell line clone containing three copies of integrated WPRE gene/cell
kindly provided by Genethon, France.
SGSH Activity
Protein was isolated from tissue and cell samples by sonication 3 5 s
at 5 mm amplitude on ice. Lysates were centrifuged at 2,045  g for
15 min at 4C. A bicinchoninic acid (BCA) assay was performed on
supernatants to determine total protein concentration (Pierce/
Thermo UK). A total of 10 mg was loaded in the SGSH assay for or-
gans and 1–5 mg for BM and pooled CFU colony samples. The SGSH
enzyme activity was performed as previously described.6,21,35 In brief,
the assay measures levels of 4-methylumbelliferone (4MU), a ﬂuores-
cent product formed by two-step hydrolysis of the substrate 4-meth-
ylumbelliferyl-alpha-N-sulpho-D-glucosaminide. The sample SGSH
activity desulfates the substrate over a 17-hr reaction at 47C, fol-
lowed by a secondary reaction with excess alpha glucosidase, releasing
the ﬂuorescent product, 4MU over 24 hrs at 37C, which is detectedMoleculby reading ﬂuorescence at excitation (Ex) 360 nm/emission (Em)
450 nm. The SGSH activity is expressed as mM 4MU released/mg
protein/17 hr or fold increase over non-transduced.
P24 ELISA
Citrated plasma was collected from PB samples. An immune complex
dissociation step was performed as described in the manufacturer’s
protocol (R&D Systems). For positive controls, citrated plasma
(from a mock-transduced NSG mouse) was spiked with un-concen-
trated lentiviral vector (CD11b.GFP LV titer 2  106 TU/mL)
and a serial dilution performed. P24 capsid was detected in the pos-
itive controls up to a dilution of 1 in 1,300 (Table S1). Urine was
collected at time of scrufﬁng prior to harvest and/or during organ
collection. The amount of urine collected ranged from 2 to 90 ml
for each mouse. The urine was made up to a total volume of 100 ml
and ran in the assay.
Flow Cytometry Analysis for Chimerism and Engraftment
Hematopoietic donor cell engraftment in MPSIIIA mice was assessed
by FACS immunostaining of isolated WBCs with anti-mouse
CD45.1-PE for donor and CD45.2-FITC for recipient hematopoietic
cells (BD PharMingen, Oxford, UK) in a 5% solution of ToPro3 io-
dide (Molecular Probes, Paisley, UK) on a BD FACS Canto II ﬂow cy-
tometer. Immunophenotype was evaluated by immunostaining with
anti-mouse CD3, CD11b and CD19 antibodies (BD PharMingen, Ox-
ford, UK). The percentage of viable CD34+CD45+ cells was assessed
by staining the cells with anti-CD34-PE and CD45-PerCP antibodies
(Miltenyi Biotec, UK) with a 7-aminoactinomycin D (7-AAD) live
versus dead stain (Thermo Fisher, UK). Human cell engraftment
and immunophenotype in transplanted NSG mice were determined
by FACS immunostaining. Cells were collected from the hematopoi-
etic organs of transplanted NSGmice, blocked with Fc receptor (FcR)
blocking reagent 1:100 (Miltenyi Biotec, UK) for 10 min at room tem-
perature and then stained for the expression of the following surface
markers: CD45-FITC, CD34-PE, CD13-APC, CD3-APC, CD4-PE,
CD8-PerCP-vio700, CD19-PerCP-vio700 (Miltenyi Biotec, UK; all
1:11) and a NIR live versus dead cell stain (Thermo Fisher, UK). A
percentage of CD45+ human cells > 1% were considered engrafted.
Compensation was performed using Ultra compensation beads and
the ArC Amine reactive compensation bead kit (Thermo Fisher,
UK). Fluorescence minus one controls (FMOs) were included in
order to evaluate ﬂow cytometry data accurately. Samples were ac-
quired on a BD FACS CANTO (Becton Dickinson), and FCS ﬁles
were exported and analyzed with FlowJo software.
Histopathology Analysis
MPSIIIA Mouse Toxicology
Brain, ear, esophagus, heart, kidneys, liver, lungs, gastrocnemius,
lumbar spinal cord, spleen, stomach, testes, thymus, and trachea
were ﬁxed in 4% paraformaldehyde (PFA) overnight and stored in
70% EtOH before being outsourced to Envigo CRO for H&E staining
and histopathology analysis along with methanol ﬁxed blood ﬁlms for
blood cell examination. Samples were sent blinded and were pro-
cessed at GLP (report FF54YX).ar Therapy: Methods & Clinical Development Vol. 13 June 2019 411
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Samples of brain, heart, kidney, liver, lungs and bronchi, ovaries,
skeletal muscle, spleen, testes, and thymus were ﬁxed in 10% neutral
buffered formalin (Sigma, UK) and outsourced to Envigo for H&E
staining and histopathology analysis along with methanol ﬁxed blood
and BM ﬁlms for blood cell examination. Samples were sent blinded
and were processed at GLP (report JC53CL).
IVIM Assay
The IVIM assay was performed as previously described.24 In brief,
cells were expanded after retroviral transduction as mass cultures
for 2 weeks in Iscove’s modiﬁed Dulbecco’s medium containing
50 ng/mL mSCF, 100 ng/mL hFlt-3 ligand, 100 ng/mL hIL-11,
10 ng/mLmouse interleukin 3 (mIL-3), 10% fetal calf serum, 1% peni-
cillin/streptomycin, and 2 mmol/L glutamine. Density was adjusted
to 5  10E5 cells/mL every 3 days. After mass culture expansion
for 14 days, cells were plated into 96-well plates at a density of
100 cells/well or 10 cells/well.24 Two weeks later, the positive wells
were counted, and the frequency of replating cells was calculated
based on Poisson statistics using L-Calc software (Stem Cell Technol-
ogies). Selected clones were expanded for further characterization.
Cryptic Splice Site Assessment
HSCs and HEK293T cells were transduced overnight with
CD11b.SGSH LV, and media refreshed and then grown for a further
72 h. Cells were harvested and gDNA eluted using the Genelute kit
(Sigma, UK). PCR was performed to amplify integrated transcripts
using forward primer 50-AGAAGGAGAGAGATGGGTGCGA
GAG-30 designed to bind just after the HIV packaging signal and
the reverse primer 50-GAAGGAAGGTCCGCTGGATTGAGG-30,
which binds toward the end of the WPRE element. Gel electropho-
resis was used to determine band sizes.
Statistical Analysis
Statistical analysis was performed using GraphPad prism software
(GraphPad Software, UK), analyzing datasets by two-way ANOVA,
unless otherwise stated.
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